Stock MORF MORPHIC HOLDING, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Morphic Holding, Inc.

Equities

MORF

US61775R1059

Real-time Estimate Cboe BZX
Other stock markets
 10:13:55 2024-04-19 am EDT 		5-day change 1st Jan Change
27.68 USD +0.64% Intraday chart for Morphic Holding, Inc. -2.32% -3.06%
Mar. 19 Morphic Holding Names Simon Cooper as Chief Medical Officer MT
Mar. 19 Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 22% by 2026.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
MORPHIC HOLDING, INC. Stock Morphic Holding, Inc.
-3.06% 1.38B
C-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.99% 41.35B
B
LONZA GROUP AG Stock Lonza Group AG
+42.27% 40.38B
A
MODERNA, INC. Stock Moderna, Inc.
+3.32% 39.05B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.06% 24.07B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.45% 18.36B
B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.86% 11.68B
C+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+23.03% 11.6B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.64% 11.15B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MORF Stock
  4. Ratings Morphic Holding, Inc.